News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

United States District Court Rules in Favor of Ivera Medical Corporation Denying Excelsior Medical Corporation, Hospira, Inc. (HSP) and Catheter Connections' Motions to Stay Patent Litigation Proceedings


1/15/2013 9:17:12 AM

SAN DIEGO, CA--(Marketwire - January 15, 2013) - On January 9, 2013 the U.S. District Court for the Southern District of California denied the motions of Excelsior Medical Corporation, Hospira, and Catheter Connections to stay patent litigations related to intellectual property held by Ivera Medical.

Ivera has brought six related patent-infringement-cases asserting three U.S. patents covering disinfecting caps used on IV sets to kill the organisms that can cause catheter-related bloodstream infections. On January 19, 2012, the Court granted the parties' joint motions to temporarily stay the first two cases pending resolution of ex parte reexaminations of U.S. Patent Nos. 7,780,794 and 7,985,302. Both of those Ivera patents were confirmed after reexamination by the U.S. Patent and Trademark Office.

Ivera's lawsuits allege that Excelsior's SwabCap and all products containing SwabCap®, Hospira's EffectIV™, and Catheter Connections' DualCap Solo™ infringe three Ivera patents. Each filed similar motions to stay their respective litigations, but the district court found that further delay will not save significant time and resources, and exercised its discretion to deny the stay requests.

This decision clears the way for Ivera's cases to go forward, with trials expected to occur in the summer of 2014.

Commenting on the District Court ruling, Ivera Medical CEO, Bob Rogers, said, "We are pleased to see the court deny another attempt by our competitors to delay a definitive ruling related to the intellectual property rights reflected in Ivera Medical's patents. Ivera has worked hard to secure these IP rights. Finally, we can look forward to having 'our day in court' where we believe this will lead to a conclusive validation our patents."

About Ivera Medical

Ivera Medical Corporation is focused on the design, development, manufacture, marketing and sale of products that help healthcare providers reduce hospital-acquired blood infections. Curos®, manufactured in Carlsbad, CA, is the first disinfecting cap to be marketed in the U.S. and has received FDA's 510(k) market clearance. For more information about Curos and Ivera Medical, visit the website at www.curos.com.


Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES